{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T22:00:05Z","timestamp":1789509605437,"version":"build-2803163510"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":23,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-33716-x","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T12:05:14Z","timestamp":1767614714000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A stability-indicating RP-HPLC method for the simultaneous quantification of brimonidine tartrate and timolol maleate in bulk drug substances and pharmaceutical dosage forms"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1478-6310","authenticated-orcid":false,"given":"Aktham","family":"Mestareehi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"key":"33716_CR1","first-page":"844","volume":"82","author":"S Resnikoff","year":"2004","unstructured":"Resnikoff, S. et al. Global data on visual impairment in the year 2002. Bull. World Health Organ. 82, 844\u2013851 (2004).","journal-title":"Bull. World Health Organ."},{"key":"33716_CR2","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.ophtha.2006.07.060","volume":"114","author":"B Bengtsson","year":"2007","unstructured":"Bengtsson, B., Leske, M. C., Hyman, L. & Heijl, A. Early manifest glaucoma trial Group. Fluctuation of intraocular pressure and glaucoma progression in the early manifest glaucoma trial. Ophthalmology 114, 205\u2013209 (2007).","journal-title":"Ophthalmology"},{"key":"33716_CR3","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1001\/archopht.120.6.701","volume":"120","author":"MA Kass","year":"2002","unstructured":"Kass, M. A. et al. The ocular hypertension treatment study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch. Ophthalmol. 120, 701\u2013713 (2002). discussion 829\u2013830.","journal-title":"Arch. Ophthalmol."},{"key":"33716_CR4","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1097\/00055735-200404000-00008","volume":"15","author":"MC Leske","year":"2004","unstructured":"Leske, M. C., Heijl, A., Hyman, L., Bengtsson, B. & Komaroff, E. Factors for progression and glaucoma treatment: the early manifest glaucoma trial. Curr. Opin. Ophthalmol. 15, 102\u2013106 (2004).","journal-title":"Curr. Opin. Ophthalmol."},{"key":"33716_CR5","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.2147\/OPTH.S47760","volume":"7","author":"E Moisseiev","year":"2013","unstructured":"Moisseiev, E., Kurtz, S., Lazar, M. & Shemesh, G. Intraocular pressure reduction using a fixed combination of timolol maleate 0.5% and brimonidine tartrate 0.2% administered three times daily. Clin. Ophthalmol. 7, 1269\u20131273 (2013).","journal-title":"Clin. Ophthalmol."},{"key":"33716_CR6","doi-asserted-by":"crossref","unstructured":"European Glaucoma Society Terminology and Guidelines for Glaucoma, 5th Edition. Br J Ophthalmol 105, 1\u2013169. (2021).","DOI":"10.1136\/bjophthalmol-2021-egsguidelines"},{"key":"33716_CR7","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1185\/030079903125001820","volume":"19","author":"K Gugleta","year":"2003","unstructured":"Gugleta, K., Org\u00fcl, S. & Flammer, J. Experience with Cosopt, the fixed combination of timolol and dorzolamide, after switch from free combination of timolol and dorzolamide, in Swiss ophthalmologists\u2019 offices. Curr. Med. Res. Opin. 19, 330\u2013335 (2003).","journal-title":"Curr. Med. Res. Opin."},{"key":"33716_CR8","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1089\/jop.2010.0032","volume":"26","author":"ACS Crichton","year":"2010","unstructured":"Crichton, A. C. S. et al. Effectiveness of dorzolamide\u2013timolol (COSOPT) in patients who were treatment Naive for open-angle glaucoma or ocular hypertension: the COSOPT first-line study. J. Ocul Pharmacol. Ther. 26, 503\u2013511 (2010).","journal-title":"J. Ocul Pharmacol. Ther."},{"key":"33716_CR9","doi-asserted-by":"publisher","first-page":"26075","DOI":"10.1021\/acsomega.4c01496","volume":"9","author":"A Mestareehi","year":"2024","unstructured":"Mestareehi, A. Global gene expression profiling and bioinformatics analysis reveal downregulated biomarkers as potential indicators for hepatocellular carcinoma. ACS Omega. 9, 26075\u201326096 (2024).","journal-title":"ACS Omega"},{"key":"33716_CR10","unstructured":"COMBIGAN\u00ae (brimonidine. tartrate\/timolol maleate ophthalmic solution) 0.2%\/0.5% | Official Patient Site. at https:\/\/www.combigan.com\/patient\/"},{"key":"33716_CR11","unstructured":"021398s007lbl. pdf. at https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/021398s007lbl.pdf"},{"key":"33716_CR12","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1089\/jop.2005.21.337","volume":"21","author":"ER Craven","year":"2005","unstructured":"Craven, E. R. et al. Brimonidine and timolol fixed-combination therapy versus monotherapy: a 3-month randomized trial in patients with glaucoma or ocular hypertension. J. Ocul Pharmacol. Ther. 21, 337\u2013348 (2005).","journal-title":"J. Ocul Pharmacol. Ther."},{"key":"33716_CR13","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ajo.2010.07.024","volume":"151","author":"GL Spaeth","year":"2011","unstructured":"Spaeth, G. L., Bernstein, P., Caprioli, J. & Schiffman, R. M. Control of intraocular pressure and fluctuation with fixed-combination brimonidine-timolol versus brimonidine or timolol monotherapy. Am. J. Ophthalmol. 151, 93\u201399e4 (2011).","journal-title":"Am. J. Ophthalmol."},{"key":"33716_CR14","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1001\/archopht.119.4.492","volume":"119","author":"LI Larsson","year":"2001","unstructured":"Larsson, L. I. Aqueous humor flow in normal human eyes treated with brimonidine and timolol, alone and in combination. Arch. Ophthalmol. 119, 492\u2013495 (2001).","journal-title":"Arch. Ophthalmol."},{"key":"33716_CR15","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.1185\/03007990802333167","volume":"24","author":"MA Motolko","year":"2008","unstructured":"Motolko, M. A. Comparison of allergy rates in glaucoma patients receiving brimonidine 0.2% monotherapy versus fixed-combination brimonidine 0.2%-timolol 0.5% therapy. Curr. Med. Res. Opin. 24, 2663\u20132667 (2008).","journal-title":"Curr. Med. Res. Opin."},{"key":"33716_CR16","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1185\/03007995.2010.482017","volume":"26","author":"J Garc\u00eda-Feijo\u00f3","year":"2010","unstructured":"Garc\u00eda-Feijo\u00f3, J. et al. Comparison of ocular hypotensive actions of fixed combinations of brimonidine\/timolol and dorzolamide\/timolol. Curr. Med. Res. Opin. 26, 1599\u20131606 (2010).","journal-title":"Curr. Med. Res. Opin."},{"key":"33716_CR17","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s10792-011-9495-z","volume":"31","author":"G Gulkilik","year":"2011","unstructured":"Gulkilik, G., Oba, E. & Odabas\u0131, M. Comparison of fixed combinations of dorzolamide\/timolol and brimonidine\/timolol in patients with primary open-angle glaucoma. Int. Ophthalmol. 31, 447\u2013451 (2011).","journal-title":"Int. Ophthalmol."},{"key":"33716_CR18","unstructured":"PubChem Brimonidine Tartrate. at pubchem.ncbi.nlm.nih.gov\/compound\/54405"},{"key":"33716_CR19","doi-asserted-by":"publisher","first-page":"10299","DOI":"10.1021\/acsomega.3c07787","volume":"9","author":"A Mestareehi","year":"2024","unstructured":"Mestareehi, A. & Abu-Farsakh, N. Impact of protein phosphatase expressions on the prognosis of hepatocellular carcinoma patients. ACS Omega. 9, 10299\u201310331 (2024).","journal-title":"ACS Omega"},{"key":"33716_CR20","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1093\/chromsci\/bmac066","volume":"61","author":"A Din\u00e7el","year":"2023","unstructured":"Din\u00e7el, A., K\u0131z\u0131ltun\u00e7, P. B., Atilla, H., Onur, F. & Demirel, S. Chromatographic analysis of aqueous humor of bupivacaine in different administration approaches. J. Chromatogr. Sci. 61, 688\u2013691 (2023).","journal-title":"J. Chromatogr. Sci."},{"key":"33716_CR21","unstructured":"PubChem Timolol Maleate. at pubchem.ncbi.nlm.nih.gov\/compound\/5281056"},{"key":"33716_CR22","unstructured":"Timolol maleate | DrugBank Online. at https:\/\/go.drugbank.com\/salts\/DBSALT000989"},{"key":"33716_CR23","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.jfda.2015.11.006","volume":"24","author":"M Walash","year":"2016","unstructured":"Walash, M. & El-Shaheny, R. Fast separation and quantification of three anti-glaucoma drugs by high-performance liquid chromatography UV detection. J. Food Drug Anal. 24, 441\u2013449 (2016).","journal-title":"J. Food Drug Anal."},{"key":"33716_CR24","doi-asserted-by":"crossref","unstructured":"Patel, A. I., Mandavia, A. K., Vyas, D. R. & Vyas, A. J. RP-HPLC method development for simultaneous Estimation of brimonidine tartrate and timolol maleate in ophthalmic Preparation. International J. Pharm. Sci. Nanotechnology(IJPSN) 16, (2023).","DOI":"10.37285\/ijpsn.2023.16.2.4"},{"key":"33716_CR25","doi-asserted-by":"crossref","unstructured":"Mathrusri Annapurna, M. Simultaneous Determination of Brimonidine Tartrate and Timolol Maleate by First Derivative and Ratio Derivative Spectroscopy. JAPLR 4, (2017).","DOI":"10.15406\/japlr.2017.04.00120"},{"key":"33716_CR26","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1093\/chromsci\/bmw160","volume":"55","author":"E B\u00fcker","year":"2017","unstructured":"B\u00fcker, E. & Din\u00e7, E. A. New UPLC method with chemometric Design-Optimization approach for the simultaneous quantitation of brimonidine tartrate and timolol maleate in an eye drop Preparation. J. Chromatogr. Sci. 55, 154\u2013161 (2017).","journal-title":"J. Chromatogr. Sci."},{"key":"33716_CR27","unstructured":"Elshanawane, A. A., Abdelaziz, L. M., Mohram, M. S. & Hafez, H. M. Development and validation of HPLC method for simultaneous Estimation of brimonidine tartrate and timolol maleate in bulk and pharmaceutical dosage form. Journal Chromatogr. & Sep. Techniques 5, 1\u20135"},{"key":"33716_CR28","doi-asserted-by":"publisher","first-page":"124573","DOI":"10.1016\/j.jchromb.2025.124573","volume":"1257","author":"A Mestareehi","year":"2025","unstructured":"Mestareehi, A. Development and validation of a stability-indicating reversed phase high-performance liquid chromatography method for quantifying Rivaroxaban (XARELTO). J. Chromatogr. B Analyt Technol. Biomed. Life Sci. 1257, 124573 (2025).","journal-title":"J. Chromatogr. B Analyt Technol. Biomed. Life Sci."},{"key":"33716_CR29","doi-asserted-by":"publisher","unstructured":"Abraham, J. in Handbook of Transnational Economic Governance Regimes (eds. Tietje, C. & Brouder, A.) 1041\u20131053 (Brill | Nijhoff, 2010). https:\/\/doi.org\/10.1163\/ej.9789004163300.i-1081.897","DOI":"10.1163\/ej.9789004163300.i-1081.897"},{"key":"33716_CR30","doi-asserted-by":"publisher","first-page":"1551189","DOI":"10.3389\/fchem.2025.1551189","volume":"13","author":"A Mestareehi","year":"2025","unstructured":"Mestareehi, A. Comprehensive and robust stability-indicating reversed phase high performance liquid chromatography (RP-HPLC) method for rivaroxaban: synergistic integration of infrared spectroscopy and clinical Pharmacology insights. Front. Chem. 13, 1551189 (2025).","journal-title":"Front. Chem."},{"key":"33716_CR31","doi-asserted-by":"crossref","unstructured":"Mestareehi, A. H., Optimized, Stability-Indicating, V. & Method, R. P. H. P. L. C. for Comprehensive Profiling of Process-Related Impurities and Stress-Induced Degradation Products in Rivaroxaban (XARELTO)\u00ae. Int J Mol Sci 26, 4744 (2025).","DOI":"10.3390\/ijms26104744"},{"key":"33716_CR32","unstructured":"FDA\/CDER\/Beers, D. Analytical Procedures and Methods Validation for Drugs and Biologics. (2015)."},{"key":"33716_CR33","unstructured":"USP 38\u2013NF 33 | USP-NF. at https:\/\/www.uspnf.com\/official-text\/proposal-statuscommentary\/usp-38-nf-33"},{"key":"33716_CR34","unstructured":"Research, C. & Q1A(R2. for D. E. and.) Stability Testing of New Drug Substances and Products. at (2020). https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/q1ar2-stability-testing-new-drug-substances-and-products"},{"key":"33716_CR35","doi-asserted-by":"publisher","first-page":"16206","DOI":"10.1021\/acsomega.3c00678","volume":"8","author":"A Mestareehi","year":"2023","unstructured":"Mestareehi, A. et al. Quantitative proteomics reveals transforming growth factor \u03b2 receptor targeted by Resveratrol and Hesperetin coformulation in endothelial cells. ACS Omega. 8, 16206\u201316217 (2023).","journal-title":"ACS Omega"},{"key":"33716_CR36","unstructured":"Purdie, F. P. Guidance for Industry. (2021)."},{"key":"33716_CR37","doi-asserted-by":"crossref","unstructured":"Mestareehi, A. et al. Metformin Increases Protein Phosphatase 2A Activity in Primary Human Skeletal Muscle Cells Derived from Lean Healthy Participants. Journal of Diabetes Research. 2021 9979234 (2021). (2021).","DOI":"10.1155\/2021\/9979234"},{"key":"33716_CR38","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.mjafi.2015.12.001","volume":"72","author":"JKS Parihar","year":"2016","unstructured":"Parihar, J. K. S. & Glaucoma The \u2018Black hole\u2019 of irreversible blindness. Med. J. Armed Forces India. 72, 3\u20134 (2016).","journal-title":"Med. J. Armed Forces India"},{"key":"33716_CR39","doi-asserted-by":"publisher","first-page":"101013","DOI":"10.1016\/j.jpha.2024.101013","volume":"14","author":"L Yin","year":"2024","unstructured":"Yin, L. et al. Green analytical chemistry metrics for evaluating the greenness of analytical procedures. J. Pharm. Anal. 14, 101013 (2024).","journal-title":"J. Pharm. Anal."},{"key":"33716_CR40","doi-asserted-by":"publisher","first-page":"100159","DOI":"10.1016\/j.greeac.2024.100159","volume":"11","author":"SI Kaya","year":"2024","unstructured":"Kaya, S. I., Ozcelikay-Akyildiz, G. & Ozkan, S. A. Green metrics and green analytical applications: A comprehensive outlook from developing countries to advanced applications. Green. Anal. Chem. 11, 100159 (2024).","journal-title":"Green. Anal. Chem."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-33716-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-33716-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-33716-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T10:08:56Z","timestamp":1769594936000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-33716-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["33716"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-33716-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7231691\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,5]]},"assertion":[{"value":"28 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors affirm that they have no financial conflicts of interest related to this work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Financial competing interests"}},{"value":"This manuscript does not involve any research conducted on human participants or animal subjects by the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statement of human and animal rights (including statement of informed consent)"}},{"value":"The datasets analyzed in this research originate exclusively from our own samples, with study approval granted by the institutional ethics committee.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}}],"article-number":"3692"}}